Molnupiravir


Source: Wikipedia


Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses, and is used to treat COVID-19 in those infected by SARS-CoV-2.[2]

Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine and exerts its antiviral action through introduction of copying errors during viral RNA replication.[4][5]

Molnupiravir was originally developed to treat influenza at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, which later partnered with Merck & Co. to develop the drug further.[6]

Molnupiravir was approved for medical use in the United Kingdom in November 2021.[1][7]

Molnupiravir.png, Nov 2021



Cont’d.

LINK:
https://en.wikipedia.org/wiki/Molnupiravir

Discusiones sobre el mismo tema

URL de retroenlace : https://www.ictal.org/index.php?trackback/2991

Fuente de los comentarios de esta entrada